The authors found a negative association between CSF-CHI3L1 levels and performance in Trail Making Test A (p = 0.016), suggesting that elevated CSF-CHI3L1 levels may indicate more severe deficits in graphokinetic speed during the early stages of MS (Table 2). The gene discussed is CHI3L1; the disease is myeloid sarcoma.